<- Go Home
TELA Bio, Inc.
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene, polyglycolic acid, and polylactic-co-glycolic acid designed to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Market Cap
$45.7M
Volume
155.7K
Cash and Equivalents
$39.5M
EBITDA
-$32.8M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$54.7M
Profit Margin
67.72%
52 Week High
$2.20
52 Week Low
$0.50
Dividend
N/A
Price / Book Value
-8.78
Price / Earnings
-1.28
Price / Tangible Book Value
-7.06
Enterprise Value
$62.0M
Enterprise Value / EBITDA
-1.92
Operating Income
-$33.8M
Return on Equity
616.62%
Return on Assets
-28.72
Cash and Short Term Investments
$39.5M
Debt
$55.9M
Equity
-$5.2M
Revenue
$80.8M
Unlevered FCF
N/A
Sector
Health Care Equipment and Supplies
Category
N/A